Table 2.
Combined mortality or hospitalization endpoints during the first 2 years after randomization by digoxin and placebo in subgroups of high-risk heart failure patients in the Digitalis Investigation Group trial
| Outcomes | % (events) |
Absolute risk differencea | Hazard ratio (95% CI) | P-value | |
|---|---|---|---|---|---|
| Digoxin | Placebo | ||||
| NYHA class III–IV | (n = 1118) | (n = 1105) | |||
| HF mortality or HF hospitalization | 29% (329) | 40% (445) | –11% | 0.65 (0.57–0.75) | <0.001 |
| All-cause mortality or all-cause hospitalization | 70% (779) | 72% (795) | –2% | 0.88 (0.80–0.97) | 0.012 |
| LVEF <25% | (n = 1127) | (n = 1129) | |||
| HF mortality or HF hospitalization | 27% (304) | 39% (444) | –12% | 0.61 (0.53–0.71) | <0.001 |
| All-cause mortality or all-cause hospitalization | 64% (716) | 68% (767) | –4% | 0.84 (0.76–0.93) | 0.001 |
| Cardiothoracic ratio >55% | (n = 1175) | (n = 1170) | |||
| HF mortality or HF hospitalization | 29% (336) | 40% (465) | –11% | 0.65 (0.57–0.75) | <0.001 |
| All-cause mortality or all-cause hospitalization | 65% (764) | 69% (805) | –4% | 0.85 (0.77–0.94) | 0.002 |
| High risk (any of the above) | (n = 2191) | (n = 2176) | |||
| HF mortality or HF hospitalization | 26% (566) | 36% (783) | –10% | 0.66 (0.59–0.73) | <0.001 |
| All-cause mortality or all-cause hospitalization | 64% (1391) | 67% (1459) | –3% | 0.87 (0.81–0.94) | <0.001 |
CI, confidence interval; HF, heart failure.
aAbsolute risk differences were calculated by subtracting percentage events in patients receiving placebo from those in patients receiving digoxin.